Tokyo, Nov 11, 2005 (JCN) - Seikagaku has identified several drug compound candidates that target sugar chain enzymes, in collaboration with its research partner Discovery Partners International (DPI).
By using Seikagaku's proprietary assay method and DPI's exclusive screening system, the two companies have discovered the compound candidates that inhibit the activity of glycosylation enzymes.
Seikagaku will proceed with research with a view to developing oral medication using the newly-discovered compounds. Any rights, including patents and development rights, regarding the compounds are vested in Seikagaku.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Seikagaku Obtains Sales Distribution Approval for MukoUp
(Oct 20, 2006)
|
|
|
Seikagaku to Begin Clinical Trials of Injectable Hyaluronic Acid Gel for Knee Osteoarthritis Treatment in US
(July 20, 2006)
|
|
|
AnGes MG, Seikagaku to Dissolve Joint Development Agreement for NFkB Decoy-Oligo-based Intraarticular Injection
(Feb 6, 2006)
|
|
|
Seikagaku to Boost ARTZ Dispo Production Capacity
(Nov 14, 2005)
|
|
|
Seikagaku, Discovery Partners International Identify Drug Compound Candidates That Target Sugar Chain Enzymes
(Nov 11, 2005)
|
|
|
Seikagaku Introduces New Reagent Kit for Basic Sodium Hyaluronate Research
(July 21, 2004)
|
|
|
Seikagaku Halts Development of New Interstitial Cystitis Drug
(Mar 10, 2004)
|
|
|
Seikagaku's US Subsidiary Receives FDA Approval for New LAL Reagent Plant
(Mar 10, 2004)
|
|
|
